Gemelli Biotech, a Los Angeles, CA and Raleigh, NC-based company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, raised $19M in Series A funding.
The round was led by Blue Ox Healthcare Partners, Cedars-Sinai, with participation from Cedars-Sinai, Carolina Angel Network, CerraCap Ventures, and several family offices.
Founded in 2018 and led by CEO Matt Mitcho, Gemelli Biotech is focused on improving health by providing precision diagnostics for GI diseases. The company leverages biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
Gemelli Biotech intends to use the funds to accelerate the commercialization of its trio-smart® and ibs-smart® precision diagnostic tests, including expanding sales and marketing across the US and the scale-up of laboratory and manufacturing capacity, as well as its operational footprints in Raleigh and Los Angeles.
trio-smart is a clinical breath test that measures levels of hydrogen, methane, and hydrogen sulfide to provide clinicians and patients with a more complete picture of gut health. ibs-smart is a patented diagnostic blood test for post-infectious irritable bowel syndrome (IBS). Both products were developed in partnership with the Medically Associated Science and Technology program at Cedars-Sinai.